AI-Powered Stock Analysis & Investment Research

Analyze over 5,500 stocks using cutting-edge AI tools. Get real-time market insights, deep company fundamentals, and smarter investment decisions.

Screener Image

Direct Access To the Stock market

Trending Investment Case Today

Stock-Card

HL

+8.19%
Stock-Card

RIG

+8.46%
Stock-Card

PCOR

+9.31%
Stock-Card

HASI

+10.80%
Stock-Card

FN

+7.25%
Stock-Card

SBSW

+7.49%
Stock-Card

VAL

+7.95%

How to find the best strategy for you ?

Card image cap

Value

Our factor investing score meticulously assesses the intrinsic value of each asset, providing invaluable insights into its potential for long-term growth.

Card image cap

Growth

With a keen focus on growth prospects, our factor investing score analyzes each asset's trajectory, offering strategic guidance for maximizing returns in dynamic market conditions..

Card image cap

Quality

With an emphasis on quality metrics, our factor investing score meticulously evaluates the fundamental strength and stability of each asset, safeguarding your portfolio against potential risks.

Card image cap

Volatility

By meticulously evaluating volatility, our factor investing score helps you navigate market turbulence, ensuring a balanced portfolio resilient to unpredictable fluctuations.

Card image cap

Momentum

Leveraging momentum analysis, our factor investing score identifies assets poised for upward trends, empowering you to capitalize on market momentum for optimized performance.

Card image cap

Yield

Focused on yield optimization, our factor investing score identifies assets with attractive income potential, enabling you to construct a diversified portfolio tailored to your income objectives.

Create a reliable strategy with the A-Score

Undervalued company with stable and reliable business like Warren Buffet

Get detailled Investment Case for more than 5500 Stocks

Image

Strong Company Updates

Get a complete corporate access : reliable, clear, and always available at the time you need it

Stock-Card
Earnings

Pinterest(PINS): Pinterest's Q4 2025 Earnings: A Strong Year for Growth and Innovation

Pinterest's Q4 2025 revenue came in at $1,319,000,000, representing a 14% year-over-year growth, with the US and Canada contributing $979,000,000 and Europe $245,000,000, growing 9% and 25%, respectively. The company's adjusted EBITDA margin is expected to be roughly in line with 2025, excluding a 100-basis-point drag from the TV Scientific acquisition. Actual EPS was $0.38, slightly below estimates of $0.4164. For the full year 2025, free cash flow increased 33% to $1,250,000,000, and the company deployed $927,000,000 towards share repurchases.

550$ (-1.8%)

A-Score: 4.9/10

Feb -12
Stock-Card
Earnings

Applied Materials(AMAT): Applied Materials' Q1 2026 Earnings: Strong Revenue and Margin Performance

Applied Materials delivered a robust Q1 2026, with revenues and earnings per share (EPS) exceeding expectations. EPS came in at $2.54, beating the estimated $2.19. The company's strong financial performance was driven by healthy demand across AI, foundry-logic, and memory, with revenue growth supported by node migrations and new 3D scaling approaches. Gross margin reflected a favorable product and customer mix, as well as continued improvements in productivity and cost.

550$ (-1.8%)

A-Score: 5.3/10

Feb -12
Stock-Card
Earnings

Vertex Pharmaceuticals(VRTX): Vertex Pharmaceuticals' Q4 2025 Earnings: Strong Performance and Growth Prospects

Vertex Pharmaceuticals reported a strong financial performance in Q4 2025, with total revenue reaching $3,200,000,000, a 10% increase compared to Q4 2024. For the full year, total revenue was $12,000,000,000, an increase of 9% versus 2024. The company's cystic fibrosis therapies remain the foundation of its revenue and cash flow, with full-year 2025 growth of 7% globally. The EPS came out at $5.03, slightly below estimates of $5.11. For 2026, the company expects total company revenue to be in the range of $12,950,000,000 to $13,100,000,000, representing 8% to 9% growth versus the prior year.

550$ (-1.8%)

A-Score: 4.0/10

Feb -12
Register Now

Quality Equity Research. Easy Access

Get started with our cost-effective equity research

Monthly Annual Up to 30% Discount

Free Trial

FREE
7 Days
  • Unlimited access to Watchlist
  • Unlimited access to screener
  • Unlimited access to AI Assistant
  • Access to US Investment Case
  • API calls limited to 10/day
  • Request new coverage
  • Premium Support
Start Free Trial

Ultimate

$99.90
per month
  • Unlimited access to Watchlist
  • Unlimited access to screener
  • Unlimited access to AI Assistant
  • Unlimited access to Investment Case
  • API calls limited to 2500/minute
  • Request new coverage
  • Premium Support
Buy Now